(Q44482980)

3 December 2017

title

Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models (English)

1 reference

3 December 2017

1 reference

Cryptosporidium parvum

object named as

Cryptosporidium parvum

1 reference

Mele R

1

1 reference

3 December 2017

Gomez Morales MA

series ordinal

2

1 reference

3 December 2017

Tosini F

series ordinal

3

1 reference

3 December 2017

Pozio E

series ordinal

4

1 reference

3 December 2017

publication date

1 July 2003

1 reference

International Journal for Parasitology

3 December 2017

published in

1 reference

3 December 2017

volume

33

1 reference

3 December 2017

issue

7

1 reference

3 December 2017

page(s)

757-764

1 reference

Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

In vitro activity of amprenavir against Pneumocystis carinii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Prophylaxis with tercef of infection-related complications after cesarean section

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

The HIV-1 protease as a therapeutic target for AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Quantitative flow cytometric evaluation of maximal Cryptosporidium parvum oocyst infectivity in a neonate mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Use of Paromomycin for Treatment of Cryptosporidiosis in Patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Protease activity associated with excystation of Cryptosporidium parvum oocysts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Antagonistic effect of human alpha-1-antitrypsin on excystation of Cryptosporidium parvum oocysts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Development of cellular immune functions in neonatal to weanling mice: relationship to Cryptosporidium parvum infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Complete development and long-term maintenance of Cryptosporidium parvum human and cattle genotypes in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Differential localisation of an Eimeria tenella aspartyl proteinase during the infection process.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Cloning and characterization of an Eimeria acervulina sporozoite gene homologous to aspartyl proteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Quantification of Cryptosporidium parvum oocysts in mouse fecal specimens using immunomagnetic particles and two-color flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Absence of weight loss during Cryptosporidium infection in susceptible mice deficient in Fas-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Treatment of HIV infection. Tolerability of commonly used antiretroviral agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Long-term survival of Cryptosporidium parvum oocysts in seawater and in experimentally infected mussels (Mytilus galloprovincialis).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Viral dynamics in human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

A role for host phosphoinositide 3-kinase and cytoskeletal remodeling during Cryptosporidium parvum infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900093-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0020-7519(03)00093-6

1 reference

3 December 2017

1 reference